| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/09/2011 | US20110135632 Methods for the modulation of angiogenesis |
| 06/09/2011 | US20110135631 Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof |
| 06/09/2011 | US20110135630 Chemical modification of antibody fragments |
| 06/09/2011 | US20110135629 EYA2S As Modifiers of the PTEN/AKT Pathway and Methods of Use |
| 06/09/2011 | US20110135624 Therapeutic composition for autoimmune conditions |
| 06/09/2011 | US20110135604 Antiviral compounds |
| 06/09/2011 | US20110135603 Inhibitors of phosphatidylinositol 3-kinase |
| 06/09/2011 | US20110135601 Bicycloaniline derivative |
| 06/09/2011 | US20110135598 Methods to diagnose and immunize against the virus causing human merkel cell carcinoma |
| 06/09/2011 | US20110135597 Uses of Mammalian Cytokine; Related Reagents |
| 06/09/2011 | US20110135594 Oxindolyl inhibitor compounds |
| 06/09/2011 | US20110135581 Methods and Compositions for Reducing Lung Inflammation in an Animal |
| 06/09/2011 | US20110135578 Mycobacterial infections |
| 06/09/2011 | US20110135577 Superparamagnetic nanoparticles IN MEDICAL THERAPEUTICS and manufacturing method THEREOF |
| 06/09/2011 | US20110135574 Methods of treating kidney disease |
| 06/09/2011 | US20110135573 Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| 06/09/2011 | US20110135570 Anti-Tumor Cell Antigen Antibody Therapeutics |
| 06/09/2011 | DE102009056884A1 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben Vaccine adjuvants and to improved methods for the preparation thereof |
| 06/09/2011 | DE102009056883A1 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben Vaccine adjuvants and to improved methods for the preparation thereof |
| 06/09/2011 | CA2783107A1 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins |
| 06/09/2011 | CA2782650A1 Arranging interaction and back pressure chambers for microfluidization |
| 06/09/2011 | CA2782639A1 Therapies for preventing or suppressing clostridium difficile infection |
| 06/09/2011 | CA2782511A1 Circulation of components during homogenization of emulsions |
| 06/09/2011 | CA2782484A1 Mybl2 peptides and vaccines containing the same |
| 06/09/2011 | CA2782406A1 Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| 06/09/2011 | CA2782333A1 J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| 06/09/2011 | CA2782330A1 Improved methods and compositions for detecting and treating cea-expressing cancers |
| 06/09/2011 | CA2782299A1 Methods for treating cancers comprising k-ras mutations |
| 06/09/2011 | CA2782271A1 Imp-3 oligopeptides and vaccines including the same |
| 06/09/2011 | CA2781682A1 Multispecific antibodies, antibody analogs, compositions, and methods |
| 06/09/2011 | CA2780425A1 Hydrophilic filtration during manufacture of vaccine adjuvants |
| 06/08/2011 | EP2330197A2 Antagonistic selective binding agents of osteoprotegerin binding protein |
| 06/08/2011 | EP2330193A1 Improved antibody molecule |
| 06/08/2011 | EP2330192A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
| 06/08/2011 | EP2330188A1 Circovirus sequences associated with porcine wasting disease (PWD) |
| 06/08/2011 | EP2330187A2 Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseases |
| 06/08/2011 | EP2330131A1 Antibodies against HER2 truncated variant CTF-611 |
| 06/08/2011 | EP2330130A1 Human monoclonal antibodies against CD20 |
| 06/08/2011 | EP2330129A2 Anti-TNF antibodies, compositions, methods and uses |
| 06/08/2011 | EP2330117A1 Genes of an otitis media isolate of nontypeable Haemophilus influenzae |
| 06/08/2011 | EP2330116A1 Replikin peptides and uses thereof |
| 06/08/2011 | EP2330115A1 Replikin peptides and uses thereof |
| 06/08/2011 | EP2330113A1 Immunological methods and compositions for the treatment of Alzheimer's disease |
| 06/08/2011 | EP2330100A1 An improved process for preparation of taxane derivatives |
| 06/08/2011 | EP2329847A2 Use of an antibody or an immunotoxin that selectively binds to CD123 to impair hematologic cancer progenitor cells |
| 06/08/2011 | EP2329846A1 Genetically engineered co-expression DNA vaccines, construction methods and uses thereof |
| 06/08/2011 | EP2329845A1 Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration |
| 06/08/2011 | EP2329844A1 Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| 06/08/2011 | EP2329843A2 Expressing Hepatitis B Virus surface antigen for vaccine preparation |
| 06/08/2011 | EP2329842A2 Interleukin-1 inhibitors in the treatment of diseases |
| 06/08/2011 | EP2329841A1 Survivin peptide vaccine |
| 06/08/2011 | EP2329840A1 Survivin peptide vaccine |
| 06/08/2011 | EP2329821A1 Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| 06/08/2011 | EP2329814A1 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer |
| 06/08/2011 | EP2329714A1 Influence of TAJ in the neuronal functions |
| 06/08/2011 | EP2328934A1 T-cell receptor antibodies and methods of use thereof |
| 06/08/2011 | EP2328932A1 Anti-cd5 antibodies |
| 06/08/2011 | EP2328931A1 Anti-hepcidin-25 selective antibodies and uses thereof |
| 06/08/2011 | EP2328930A1 Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) |
| 06/08/2011 | EP2328929A2 Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases |
| 06/08/2011 | EP2328928A2 Conserved influenza hemagglutinin epitope and antibodies thereto |
| 06/08/2011 | EP2328926A1 Treatment of thrombocytopenia |
| 06/08/2011 | EP2328923A2 Cd133 epitopes |
| 06/08/2011 | EP2328921A2 Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| 06/08/2011 | EP2328914A1 Prevention, treatment and diagnosis of p.gingivalis infection |
| 06/08/2011 | EP2328913A2 Antimicrobial protein compositions and production therefor from marine bacteria |
| 06/08/2011 | EP2328617A2 Carrier system for biological agents containing organosilicon compounds and uses thereof |
| 06/08/2011 | EP2328616A1 Compositions and methods for antibodies targeting complement protein c5 |
| 06/08/2011 | EP2328615A2 Engineered anti-il-13 antibodies, compositions, methods and uses |
| 06/08/2011 | EP2328614A1 Microparticles for use in immunogenic compositions |
| 06/08/2011 | EP2328613A1 Vaccine |
| 06/08/2011 | EP2328612A1 Vaccine against highly pathogenic porcine reproductive and respiratory syndrome (hp prrs) |
| 06/08/2011 | EP2328611A2 Compositions and methods for treating s.pneumoniae infection |
| 06/08/2011 | EP2328610A2 Nematode vaccine |
| 06/08/2011 | EP2328600A1 Hig2 and urlc10 epitope peptide and vaccines containing the same |
| 06/08/2011 | EP2328571A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 06/08/2011 | EP2328570A2 Method and formulation for treating adverse biological conditions |
| 06/08/2011 | EP2328559A2 Novel antibody formulation |
| 06/08/2011 | EP1817584B1 Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 |
| 06/08/2011 | EP1573022B1 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer |
| 06/08/2011 | EP1531800B1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 06/08/2011 | EP1502599B1 Use of mutated VEGF for antiangiogenic therapy |
| 06/08/2011 | EP1485127B1 Administration of agents for the treatment of inflammation |
| 06/08/2011 | EP1276500B1 Blocking leukocyte emigration and inflammation by interfering with cd99/hec2 |
| 06/08/2011 | EP1259259B1 Mucosal adjuvant formulation |
| 06/08/2011 | EP1078093B1 Vaccines, immunotherapeutics and methods for using the same |
| 06/08/2011 | EP0996423B1 A method for producing jelly sweets which contain antibodies |
| 06/08/2011 | EP0960936B1 Reconstituted human anti-hm1.24 antibody |
| 06/08/2011 | EP0914142B1 Peptides with increased binding affinity for at least three hla-a3-like molecules |
| 06/08/2011 | CN1893979B Remedy for angitis |
| 06/08/2011 | CN1852736B Immunoglobulin chimeric monomer-dimer hybrids |
| 06/08/2011 | CN1784242B A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| 06/08/2011 | CN1744883B Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 06/08/2011 | CN102089432A Soluble recombinant influenza antigens |
| 06/08/2011 | CN102089328A Mutants of streptokinase and their covalently modified forms |
| 06/08/2011 | CN102089327A Anti-PirB antibodies |
| 06/08/2011 | CN102089324A Compositions and methods for the therapy and diagnosis of influenza |
| 06/08/2011 | CN102089005A Staphylococcus aureus-specific antibody preparations |
| 06/08/2011 | CN102089004A Pharmaceutical composition for treatment and prevention of cancer |
| 06/08/2011 | CN102089003A Recombinant rhinovirus vectors |